APVO vs. SPRC, BFRI, CYCN, EGRX, AIMD, ADXN, OBSV, NLSP, SNGX, and ORGS
Should you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include SciSparc (SPRC), Biofrontera (BFRI), Cyclerion Therapeutics (CYCN), Eagle Pharmaceuticals (EGRX), Ainos (AIMD), Addex Therapeutics (ADXN), ObsEva (OBSV), NLS Pharmaceutics (NLSP), Soligenix (SNGX), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical products" industry.
Aptevo Therapeutics vs.
SciSparc (NASDAQ:SPRC) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.
Aptevo Therapeutics has a consensus price target of $10,952.00, suggesting a potential upside of 245,460.54%. Given Aptevo Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aptevo Therapeutics is more favorable than SciSparc.
In the previous week, SciSparc had 3 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 3 mentions for SciSparc and 0 mentions for Aptevo Therapeutics. SciSparc's average media sentiment score of 0.51 beat Aptevo Therapeutics' score of 0.50 indicating that SciSparc is being referred to more favorably in the media.
SciSparc's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.
SciSparc has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.11, suggesting that its share price is 411% more volatile than the S&P 500.
Aptevo Therapeutics received 197 more outperform votes than SciSparc when rated by MarketBeat users. However, 66.67% of users gave SciSparc an outperform vote while only 50.13% of users gave Aptevo Therapeutics an outperform vote.
SciSparc has higher earnings, but lower revenue than Aptevo Therapeutics.
25.1% of SciSparc shares are owned by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are owned by institutional investors. 1.5% of SciSparc shares are owned by insiders. Comparatively, 0.1% of Aptevo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
SciSparc beats Aptevo Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Aptevo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptevo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APVO) was last updated on 1/21/2025 by MarketBeat.com Staff
Free APVO Stock Alerts